Recombinant Human CD59 Protein，His

CD59, an important glycoprotein expressed on the surface of various cell types, plays a pivotal role in the regulation of the complement system, which is part of the innate immune response. It functions as an inhibitor of the membrane attack complex (MAC) formation, thus preventing lysis of host cells by complement proteins. The significance of CD59 in immune response and its involvement in various diseases, including autoimmune disorders, infections, and cancers, has spurred research into its structural and functional properties. Recombinant CD59 proteins are generated to study the mechanisms of complement inhibition and to explore therapeutic applications. Through techniques like genetic engineering and protein expression systems, researchers aim to produce functional and high-yield CD59 variants. These recombinant proteins not only serve as valuable tools for understanding the nuances of complement regulation but also hold potential for therapeutic interventions, such as enhancing tissue protection during complement-mediated damage or developing novel treatments for complement-related pathologies. Advanced studies on CD59, including its interactions with other complement components and the design of engineered variants, are crucial for unraveling its role in immune modulation and for paving the way for new therapeutic strategies. The ongoing research into CD59 recombinant proteins highlights their importance in both fundamental immunology and potential clinical applications.